Literature DB >> 26917231

CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma.

Mizue Hasegawa1, Fumikazu Sakai2, Rinako Ishikawa3, Fumiko Kimura2, Hironori Ishida4, Kunihiko Kobayashi3.   

Abstract

INTRODUCTION: The purpose of this study was to analyze the high-resolution computed tomography (HRCT) features of lung carcinoma on the basis of epidermal growth factor receptor gene (EGFR) mutation status.
METHODS: A total of 263 consecutive patients in whom lung adenocarcinoma was diagnosed at our institution between January 2010 and December 2011 were enrolled in the study. All patients underwent HRCT and analysis of EGFR mutation status. The HRCT findings were retrospectively analyzed for tumor size, multiple bilateral lung metastases, convergence of surrounding structures, surrounding ground-glass opacity, prominent peribronchovascular extension, air bronchogram, notch, pleural indentation, spiculation, cavity, and pleural effusions.
RESULTS: EGFR mutations were demonstrated in 103 patients (39.2%); the remaining 160 patients (60.8%) had the nonmutated type of adenocarcinoma. Compared with the nonmutated group, the mutated group had significantly higher frequencies of multiple bilateral lung metastases (p = 0.0152), convergence of surrounding structures (p < 0.0001), ground-glass opacity (p = 0.0011), and notch (p = 0.0428), but significantly lower frequencies of cavitation (p = 0.0004) and pleural effusions (p = 0.0064). The frequencies of the other CT findings were similar between the two groups. The devised prediction HRCT score for EGFR mutation was 78.4% sensitive and 70.4% specific.
CONCLUSIONS: EGFR-mutated adenocarcinoma showed significantly higher frequencies of multiple bilateral lung metastases, convergence of surrounding structures, surrounding ground glass opacity, and notch at HRCT compared with the non-EGFR-mutated type. Conversely, EGFR-mutated adenocarcinoma showed cavity and pleural effusions less frequently than the nonmutated type did.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computed tomography; Epidermal growth factor receptor mutation; Lung adenocarcinoma; Lung cancer

Mesh:

Substances:

Year:  2016        PMID: 26917231     DOI: 10.1016/j.jtho.2016.02.010

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  24 in total

1.  Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.

Authors:  Xinguan Yang; Xiao Dong; Jiao Wang; Weiwei Li; Zhuoran Gu; Dashan Gao; Nanshan Zhong; Yubao Guan
Journal:  Oncologist       Date:  2019-04-01

2.  Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.

Authors:  Juheon Lee; Yi Cui; Xiaoli Sun; Bailiang Li; Jia Wu; Dengwang Li; Michael F Gensheimer; Billy W Loo; Maximilian Diehn; Ruijiang Li
Journal:  Eur Radiol       Date:  2017-08-07       Impact factor: 5.315

Review 3.  Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.

Authors:  Jian-Wei Gao; Stefania Rizzo; Li-Hong Ma; Xiang-Yu Qiu; Arne Warth; Nobuhiko Seki; Mizue Hasegawa; Jia-Wei Zou; Qian Li; Marco Femia; Tang-Feng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

4.  Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.

Authors:  Naokazu Watari; Kakuhiro Yamaguchi; Hiroaki Terada; Kosuke Hamai; Ken Masuda; Yoshifumi Nishimura; Shinjiro Sakamoto; Takeshi Masuda; Yasushi Horimasu; Shintaro Miyamoto; Taku Nakashima; Hiroshi Iwamoto; Hiroyasu Shoda; Nobuhisa Ishikawa; Kazunori Fujitaka; Kozue Miyazaki; Yoshihiro Miyata; Hironobu Hamada; Kazuo Awai; Noboru Hattori
Journal:  BMC Pulm Med       Date:  2022-06-30       Impact factor: 3.320

Review 5.  Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis.

Authors:  Andrés Felipe Herrera Ortiz; Mateo E Garland; Bassel Almarie
Journal:  Cureus       Date:  2022-05-29

6.  Ground glass opacity: can we correlate radiological and histological features to plan clinical decision making?

Authors:  Duvuru Ram; Holly Egan; Tharumenthiran Ramanathan
Journal:  Gen Thorac Cardiovasc Surg       Date:  2022-05-07

7.  Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer.

Authors:  Gino In; Jeremy Mason; Sonia Lin; Paul K Newton; Peter Kuhn; Jorge Nieva
Journal:  Converg Sci Phys Oncol       Date:  2017-07-13

8.  A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD).

Authors:  Ying Zhu; Yu-Biao Guo; Di Xu; Jing Zhang; Zhen-Guo Liu; Xi Wu; Xiao-Yu Yang; Dan-Dan Chang; Min Xu; Jing Yan; Zun-Fu Ke; Shi-Ting Feng; Yang-Li Liu
Journal:  Ann Transl Med       Date:  2021-04

Review 9.  Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.

Authors:  Ailbhe C O'Neill; Jyothi P Jagannathan; Nikhil H Ramaiya
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

10.  Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.

Authors:  Yiyuan Cao; Haibo Xu; Meiyan Liao; Yanjuan Qu; Liying Xu; Dongyong Zhu; Bicheng Wang; Sufang Tian
Journal:  Int J Clin Oncol       Date:  2017-10-07       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.